




RealRate

PHARMACEUTICAL 2023

VYNE Therapeutics Inc
Rank 194 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of VYNE Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 45% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	38,275
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	2,483
Other Compr. Net Income	0
Other Expenses	13
Other Liabilities	9,345
Other Net Income	11,098
Other Revenues	477
Property and Equipment	0
Research and Development	18,385
Selling, General and Administrative Expense	16,387

Output Variable	Value in 1000 USD
Assets	40,758
Liabilities	9,345
Expenses	34,785
Revenues	477
Stockholders Equity	31,413
Net Income	-23,210
Comprehensive Net Income	-23,210
BaseVar	48,232
ECR before Limited Liability	181%
Economic Capital Ratio	289%